Vistin Pharma ASA: Business Overview, Financials & Competitive Analysis
Vistin Pharma is Europe's sole dedicated Metformin Hydrochloride (HCl) producer, supplying leading international pharmaceutical companies. The company is doubling its production capacity to supply the growing need for...
Cyborg Score thesis
Focused pharmaceutical ingredients player capturing growing global diabetes market with strong balance sheet and unique European...
Read the full analyst-debate transcript →Get the Latest Vistin Pharma ASA Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeVistin Pharma ASA Overview
Pro stress-test →Vistin Pharma is Europe's sole dedicated Metformin Hydrochloride (HCl) producer, supplying leading international pharmaceutical companies. The company is doubling its production capacity to supply the growing need for Type 2 diabetes medicine globally.
Strategic Profile
Pro stress-test →As a well-positioned sole European supplier, Vistin holds a defensible market position with exclusive geographic focus. The company maintains a strong balance sheet with an 81% equity ratio and net cash position. Revenue grew 44% year-over-year to NOK 438 million in 2023, demonstrating robust market demand for diabetes treatments.
Competitive Landscape
Pro stress-test →Vistin operates in the pharmaceutical active pharmaceutical ingredients (API) market with minimal direct competitors in Europe for Metformin HCl production. Primary competition comes from non-European producers, primarily in Asia. The company's exclusive geographic positioning and FDA-inspected manufacturing facilities provide significant competitive barriers.
Industry Context
Vistin Pharma ASA operates in Pharmaceutical Active Pharmaceutical Ingredients (API) Manufacturing.
Key facts
Headquarters: Oslo, Norway · Revenue: NOK 438M (2023) · Market cap: N/A